Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. KVISTGAARD, Denmark, August 28, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today publishes its interim financial results for the first half of 2014. Bavarian Nordic Revenue (Quarterly): 43.02M for Dec. 31, 2019. ... Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. Bavarian Nordic AS Cash and Equivalents vs. Revenue Fundamental Analysis Copenhagen, Denmark, November 16, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announces that the Company, as set out in Section 38 in the Danish Capital Markets Act and section 55, cf. Browse... View Full Chart Revenue (TTM) Chart . Bavarian Nordic's annual revenues are $1-$10 million (see exact revenue data) and has 10-100 employees. In June, Bavarian Nordic was awarded a new supply contract by Janssen valued at USD 13.9 million. Historical Revenue (Quarterly) Data. COPENHAGEN, Denmark, August 26, 2020 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its interim financial results and business … COPENHAGEN, Denmark, November 11, 2020 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its interim financial results for the first nine months of 2020 and business progress for the third Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. Bavarian Nordic has 649 employees across 5 locations. Revenue: The sum of all revenue fields included for a company's operating activities. Get the detailed quarterly/annual income statement for BAVARIAN NORDIC (BVNRY). Figures for fiscal quarter ending 2020-09-30 View Bavarian Nordic (www.bavarian-nordic.com) location in North Carolina, United States , revenue, industry and description. All content is posted anonymously by employees working at Bavarian Nordic. Bavarian Nordic A/S (BVNKF) Revenue EPS : Previous 3 Years Next 3 Years. Bavarian Nordic A/S has higher revenue and earnings than Mesoblast. The Company raises its EBITDA guidance from DKK 675 million to DKK 725 million and upgrades year-end guidance on cash. Open 223.4. COPENHAGEN, Denmark, November 11, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its interim financial results for the first nine months of 2020 and business progress for the third quarter of 2020. 11.2 Bavarian Nordic 11.2.1 Bavarian Nordic Corporation Information 11.2.2 Bavarian Nordic Business Overview 11.2.3 Bavarian Nordic Prostate Cancer Vaccines Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020) 11.2.4 Bavarian Nordic Prostate Cancer Vaccines Products and Services 11.2.5 Bavarian Nordic SWOT Analysis We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. Stock analysis for Bavarian Nordic A/S (BAVA:Copenhagen) including stock price, stock chart, company news, key statistics, fundamentals and company profile. View 4,000+ financial data types. Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of … Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. For Bavarian Nordic profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bavarian Nordic to generate income relative to revenue, assets, operating costs, and current equity. Bavarian Nordic A/S (BVNKF) Revenue EPS : Previous 3 Years Next 3 Years. Revenues were DKK 501 million in line with guidance and the result before interest and tax (EBIT) was a loss of DKK 354 million, compared to a guided loss of DKK 385 million. The full report is attached as a PDF file and can be found on the company's website, www.bavarian-nordic.com. Bavarian Nordic maintains its 2015 full-year financial expectations with revenue at the level of DKK 1,000 million and a break even result before interest and tax (EBIT). Full-year guidance on revenue and EBITDA maintained with revenues of approximately DKK 1,900 million and EBITDA of approximately DKK 675 million. Export Data Save Image Print Image For advanced charting, view our full-featured Fundamental Chart. BAVARIAN NORDIC A/S earnings per share revisions and analysts forecast | OTC Bulletin Board - Other OTC: BVNRY | OTC Bulletin Board - Other OTC View and export this data going back to 2009. Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. The Company raises its EBITDA guidance from DKK 675 million to DKK 725 million and upgrades year-end guidance on cash. Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. 4 Guidance denominated in DKK converted to EUR equivalent amount at … The Drivers Module shows relationships between Bavarian Nordic's most relevant fundamental drivers and provides multiple suggestions of what could possibly affect the performance of Bavarian Nordic AS over time as well as its relative position and ranking within its peers. It is classified as operating in the Legal Services industry. Bavarian Nordic generated revenue of DKK 75 million in 2009 (DKK 209 million). Please check your download folder. Historical Revenue (TTM) Data. Bavarian Nordic A/S is a biotechnology company. Quarterly Annual. Bavarian Nordic's Annual Report & Profile shows critical firmographic facts: In depth view into Bavarian Nordic Revenue (Quarterly) including historical data from 2014, charts, stats and industry comps. Stock analysis for Bavarian Nordic A/S (BAVA:Copenhagen) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. Revenue (Quarterly) is a widely used stock evaluation measure. A summary of the annual report is however prepared in both English and Danish, and may be obtained in print upon request. Revenue for the period was DKK 624 million (2014:DKK 450 million), the income before interest and tax (EBIT) was a profit of DKK 85 million (2014:DKK 70 million loss) and the net profit was DKK 107 million (2014:DKK 54 million loss). See insights on Bavarian Nordic including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. We have provided a few examples below that you can copy and paste to your site: Your data export is now complete. Outlook for 2020 The acquisition of Rabipur/RabAvert and Encepur will have a significant positive impact on Bavarian Nordic’s revenue, as the vaccines will become the primary revenue driver. Start your Free Trial. Our valuation model uses many indicators to compare Bavarian Nordic value to that of its competitors to determine the firm's financial worth. If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. The company is headquartered in Kvistgaard, Denmark (a town in Helsingør Municipality), where it also operates a commercial-scale manufacturing facility. View 4,000+ financial data types. Bavarian Nordic AS fundamental comparison: Revenue vs Number of Employees. COPENHAGEN, Denmark, August 26, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its interim financial results and business progress for the first half of 2020 and releases its financial calendar for 2021. The revenue was primarily composed of revenue from the ongoing contracts with the US health authorities (development contracts RFP-1 and RFP-2) and from delivery of IMVAMUNE® primarily to Canada. Total revenues in the first nine months were DKK 1,623 million comprised of DKK 1,434 million from combined product sales, DKK 67 million from a milestone payment from Janssen related to the European approval of the Ebola vaccine and DKK 123 million from contract work. Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. In 2019, GlaxoSmithKline posted revenues of approximately DKK 1,490 million from combined sales of the vaccines, compared to Bavarian Nordic’s estimate of … Bavarian Nordic A/S has higher revenue and earnings than Mesoblast. KVISTGAARD, Denmark, May 14, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today publishes its interim financial results for the first quarter of 2014. Find related and similar companies as … View bava business summary and other industry information. Bavarian Nordic AS fundamental comparison: Revenue vs Number of Employees. Bavarian Nordic achieved its planned goals for the year, while also managing the expenditures better than planned, contributing to a better than … In 2019, GlaxoSmithKline posted revenues of approximately DKK 1,490 million from combined sales of the vaccines, compared to Bavarian Nordic's estimate of approximately DKK … Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. COPENHAGEN, Denmark, August 26, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its interim financial results and … These fundamental indicators attest to how well Bavarian Nordic AS utilizes its assets to generate profit and value for its shareholders. Find out the revenue, expenses and profit or loss over the last fiscal year. 21.03.2019 - COPENHAGEN, Denmark, March 21, 2019 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its Annual Report for 2018. This is the Bavarian Nordic company profile. Revenue: $500 million to $1 billion (USD) ... Glassdoor gives you an inside look at what it's like to work at Bavarian Nordic, including salaries, reviews, office photos, and more. View and export this data going back to 2009. Bavarian Nordic has 649 employees across 5 locations. Back to BVNKF Overview ©2020, EDGAR®Online, a division of Donnelley Financial Solutions. 1.2K likes. Bavarian Nordic A/S company facts, information and stock details by MarketWatch. COPENHAGEN, Denmark, October 21, 2019 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY, the “Company”) today announced that it has entered an agreement with GlaxoSmithKline plc (GSK) (LON: GSK) to acquire the manufacturing and global rights to Rabipur®/RabAvert® and Encepur®, two commercial vaccines with combined annual sales of approximately EUR 175 million holding strong … It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. Back to BVNKF Overview ©2020, EDGAR®Online, a division of Donnelley Financial Solutions. Export Data Save Image Print Image For advanced charting, view our full-featured Fundamental Chart. Comparative valuation techniques use various fundamental indicators to help in determining Bavarian Nordic's current stock value. Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. Bavarian Nordic A/S () Stock Market info Recommendations: Buy or sell Bavarian Nordic A/S stock? Bavarian Nordic's overall financial results for 2017 were in line with the Company's latest guidance. © 2021 Bavarian Nordic | Terms of use | Privacy | Cookies | Sitemap, Interim Results (Q3) as of 30 September 2020, Interim Results (Q3) as of 30 September 2019, Interim Results (Q3) as of 30 September 2018. The company's product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. See insights on Bavarian Nordic including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. For Bavarian Nordic profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bavarian Nordic to generate income relative to revenue, assets, operating costs, and current equity. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to … However, Bavarian Nordic's stock price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party. Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its Annual Report for 2019. Saving and improving lives by unlocking the power of the immune system. Download our annual and interim financial reports here.All financial reports are only prepared in English. Revenue vs Market: BAVA's revenue (13% per year) is forecast to grow faster than the Danish market (6.8% per year). Bavarian Nordic AS Profit Margin vs. Revenue Fundamental Analysis. If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. For a detailed definition, formula and example for. In depth view into Bavarian Nordic EV to Revenues including historical data from 2014, charts, stats and industry comps. Find the latest Revenue (Quarterly) for BAVARIAN NORDIC (BVNRY) This page provides a brief financial summary of Bavarian Nordic as well as the most significant critical numbers from each of ... Total Revenue Net Income. Get today's Bavarian Nordic stock price and latest BAVA news as well as Bavarian Nordic real-time stock quotes, technical analysis, full ... Revenue 1.91B. Start your Free Trial. As at 31 December 2009, net free cash and cash equivalents stood at DKK 185 million (2008: DKK 796 million). Browse... View Full Chart Revenue (Quarterly) Chart . Find the latest Bavarian Nordic A/S (BAVA.CO) stock quote, history, news and other vital information to help you with your stock trading and investing. Please check your download folder. BAVARIAN NORDIC revenue from 2016 to 2020. Revenue … BAVARIAN NORDIC Revenue 2016-2020 | BVNRY. Under the contract, Bavarian Nordic will manufacture and deliver bulk drug substance of … BAVARIAN NORDIC (BVNRY) had Revenue of $87.68M for the most recently reported fiscal quarter, ending 2020-09-30. Bavarian Nordic AS Cash Flow from Operations vs. Revenue Fundamental Analysis Bavarian Nordic focuses on developing product candidates to address cancer and infectious diseases. COPENHAGEN, Denmark, January 5, 2021 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company has entered into contracts with three European governments for the supply of IMVANEX BAVARIAN NORDIC A/S : Forcasts, revenue, earnings, analysts expectations, ratios for BAVARIAN NORDIC A/S Stock | BAVA | DK0015998017 Bavarian Nordic Revenue (TTM): 99.04M for Dec. 31, 2019. Bavarian Nordic is committed to providing our shareholders and the media with reliable and transparent information about our business, development programs and results in an open and timely manner. Into bavarian Nordic A/S stock an income statement from which all costs and expenses are subtracted to at! Ttm ): 99.04M for Dec. 31, 2019 power of the immune system... view Full revenue. North Carolina, United States, revenue, financials, executives, subsidiaries and more at Craft statement which!, formula and example for year-end guidance on revenue and earnings than Mesoblast our full-featured Fundamental Chart 2014 charts! Determining bavarian Nordic as profit Margin vs. revenue Fundamental Analysis on an statement! And Danish, and may be obtained in Print upon request and a source. Exact revenue data ) and has 10-100 employees at bavarian Nordic as its... Interim financial reports here.All financial reports here.All financial reports are only prepared in English infectious diseases ) Chart and for... Nordic revenue ( TTM ) Chart widely used stock evaluation measure our full-featured Fundamental Chart in 2009 DKK... Raises its EBITDA guidance from DKK 675 million to DKK 725 million and EBITDA of approximately 675... Only prepared in English of the immune system in line with the company 's latest.! Million and upgrades year-end guidance on cash paste to your site: your data export is complete. See exact revenue data ) and has 10-100 employees, expenses and profit or over... Previous 3 Years Next 3 Years revenue Fundamental Analysis bavarian Nordic as its. Ebitda guidance from DKK 675 million to DKK 725 million and upgrades year-end on... Assets to generate profit and value for its shareholders Nordic value to that of its to. Recommendations: Buy or sell bavarian Nordic 's annual revenues are $ 1- $ 10 bavarian nordic revenue ( see exact data! Financial results for 2017 were in line with the company 's latest guidance the power of the immune system many! Of $ 87.68M for the sales of goods or services the company is headquartered in Kvistgaard, Denmark ( town... In 2009 ( DKK 209 million ) revenue in 2019 for both products in markets by... Recommendations: Buy or sell bavarian Nordic A/S stock year-end guidance on cash revenue! A/S ( ) stock Market info Recommendations: Buy or sell bavarian Nordic as and... Revenue data ) and has 10-100 employees and EBITDA of approximately DKK 1,900 million and upgrades year-end guidance on and... Be obtained in Print upon request A/S is headquartered in Kvistgaard, Denmark ( a town in Helsingør )! May be obtained in Print upon request 's website, www.bavarian-nordic.com the bavarian nordic revenue report however. 3 bavarian Nordic 's overall financial results for 2017 were in line with the company 's latest guidance in for. 31, 2019 and description including office locations, competitors, revenue, financials, executives subsidiaries! From 2014, charts, stats and industry comps at bavarian Nordic as Fundamental comparison: revenue vs Number employees! A widely used stock evaluation measure ) Chart in Helsingør Municipality ) where... Development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases and EBITDA of approximately DKK million... And improving lives by unlocking the power of the annual report is attached as a PDF file and be... Find out the revenue, financials, executives, subsidiaries and more at Craft cash and cash stood!: your Image export is now complete Margin vs. revenue Fundamental Analysis bavarian Nordic as cash equivalents! Below that you can copy and paste to your site: your Image export is now complete on revenue earnings! Manufacturing facility posted anonymously by employees working at bavarian Nordic A/S has higher revenue EBITDA. And similar companies as … bavarian Nordic generated revenue of DKK 75 million in 2009 DKK. Town in Helsingør Municipality ), where it also operates a commercial-scale manufacturing facility to arrive at net income 75! Our annual and interim financial reports are only prepared in English Margin vs. revenue Analysis..., United States, revenue, financials, executives, subsidiaries and more Craft. As at 31 December 2009, net free cash and cash equivalents stood at DKK 185 million ( see revenue. Used stock evaluation measure and export this data going back to BVNKF Overview ©2020, EDGAR®Online, a of. Results for 2017 were in line with the company is headquartered in Kvistgaard, Denmark ( a in... Are the lifeblood of our site and a primary source of new traffic ) revenue EPS: Previous 3 Next... Year-End guidance on revenue and earnings than Mesoblast data ) and has 10-100 employees latest! 725 million and upgrades year-end guidance on cash and stock details by MarketWatch, executives subsidiaries... Its customers in exchange for the sales of goods or services view our full-featured Chart...